Literature DB >> 32436829

Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study.

Siyamak Shahab1, Masoome Sheikhi2.   

Abstract

Triazavirin (2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-7(4H)-one, TZV) is an antiviral drug synthesized. TZV is being investigated for potential application against the Coronavirus 2019-nCoV. In order to find candidate drugs for 2019-nCoV, we have carried out a computational study to screen for effective available drug Triazavirin (C5H4N6O3S) which may work as inhibitor for the Mpro of 2019-nCoV. In the present work, first time the molecular structure of title molecule has been investigated using Density Functional Theory (DFT/B3LYP/MidiX) in gas phase. The molecular HOMO-LUMO, excitation energies and oscillator strengths of investigated compound have also been calculated and presented. The interaction of TZV compound with the Coronavirus was performed by molecular docking studies. Therefore, TZV can be used for potential application against the Coronavirus 2019-nCoV. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  DFT; Triazavirin; coronavirus; electronic properties; molecular docking

Year:  2020        PMID: 32436829     DOI: 10.2174/1566524020666200521075848

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  6 in total

1.  Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks.

Authors:  Yuchen Zhang; Xiujuan Lei; Yi Pan; Fang-Xiang Wu
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

Review 2.  SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets.

Authors:  Jayalakshmi Vallamkondu; Albin John; Willayat Yousuf Wani; Suguru Pathinti Ramadevi; Kishore Kumar Jella; P Hemachandra Reddy; Ramesh Kandimalla
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-06-27       Impact factor: 5.187

Review 3.  Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.

Authors:  Lei Zhao; Song Li; Wu Zhong
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

4.  Development of Drugs with Direct Antiviral Action Based on Azaheterocyclic Systems.

Authors:  V N Charushin; V L Rusinov; M V Varaksin; O N Chupakhin; O P Kovtun; A A Spasov
Journal:  Her Russ Acad Sci       Date:  2022-09-06       Impact factor: 0.552

Review 5.  Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches.

Authors:  Magda Gioia; Chiara Ciaccio; Paolo Calligari; Giovanna De Simone; Diego Sbardella; Grazia Tundo; Giovanni Francesco Fasciglione; Alessandra Di Masi; Donato Di Pierro; Alessio Bocedi; Paolo Ascenzi; Massimo Coletta
Journal:  Biochem Pharmacol       Date:  2020-09-19       Impact factor: 5.858

Review 6.  COVID-19: Myths and Reality.

Authors:  Larisa V Kordyukova; Andrey V Shanko
Journal:  Biochemistry (Mosc)       Date:  2021-07       Impact factor: 2.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.